Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry

The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry evaluated treatments/outcomes in node-positive breast cancer patients who were Recurrence Score-tested through Clalit Health Services from 1/2...

Descripción completa

Detalles Bibliográficos
Autores principales: Stemmer, Salomon M., Steiner, Mariana, Rizel, Shulamith, Geffen, David B., Nisenbaum, Bella, Peretz, Tamar, Soussan-Gutman, Lior, Bareket-Samish, Avital, Isaacs, Kevin, Rosengarten, Ora, Fried, Georgeta, McCullough, Debbie, Svedman, Christer, Shak, Steven, Liebermann, Nicky, Ben-Baruch, Noa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591314/
https://www.ncbi.nlm.nih.gov/pubmed/28900632
http://dx.doi.org/10.1038/s41523-017-0033-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591314/
https://www.ncbi.nlm.nih.gov/pubmed/28900632
http://dx.doi.org/10.1038/s41523-017-0033-7

Ejemplares similares